Clinical Trials
163 trialsTivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
ZAMBONI
University of California, San Francisco
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
National Cancer Institute (NCI)
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
DICE
Cancer Trials Ireland
TOMBOLA
Aarhus University Hospital
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
M.D. Anderson Cancer Center
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Rutgers, The State University of New Jersey
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Northwestern University
Circulating Tumor DNA Response In Urothelial Cancer
University of Oklahoma
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy
University Health Network, Toronto
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
University of Wisconsin, Madison
SPARK
University of Texas Southwestern Medical Center
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
PAVO
Tempus AI
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Memorial Sloan Kettering Cancer Center
AGADIR
Institut Bergonié
PANTHER
Duke University
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
AUREA
Spanish Oncology Genito-Urinary Group
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Elevation Oncology
LoMP II
University Hospital, Ghent
FAUNUS
Ankara University
Study of INCB086550 in Select Solid Tumors
Incyte Corporation
High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
University of California, San Diego
IL2HD
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
STORM
University Hospital, Ghent
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
SELECT
Beth Israel Deaconess Medical Center
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
AdventHealth
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
ERICA
University of Michigan Rogel Cancer Center
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
DART
University Hospital, Ghent
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
BAY88-8223, Dose Finding Study in Patients With HRPC
Bayer
LODESTAR
pharmaand GmbH
Parsabiv-MBD
Columbia University
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Endocyte
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)
M.D. Anderson Cancer Center
PIVOT-10
Nektar Therapeutics